MAPT and Alzheimer disease: In ALFA+, we used the biomarker-based AT classification21,22 to study 2 stages in preclinical AD: Aβ+ but tau– (A+T–) and Aβ+ and tau+ (A+T+) and compared it with the A–T– stage.